Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of alzheimer's disease

Archiv der Pharmazie

Volumn 346, Issue 12, 2013, Pages 865-871

  Chen, Yao ^a,b   Sun, Jianfei ^a   Peng, Sixun ^a   Liao, Hong ^a   Zhang, Yihua ^a   Lehmann, Jochen ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Alzheimer's disease; Amyloid ; Cholinesterase inhibitor; Flurbiprofen; Tacrine

Indexed keywords

2 (2 FLUOROBIPHENYL 4 YL) N [6 (1,2,3,4 TETRAHYDROACRIDIN 9 YLAMINO)HEXYL]PROPANAMIDE; 2 (2 FLUOROBIPHENYL 4 YL) N [8 (1,2,3,4 TETRAHYDROACRIDIN 9 YLAMINO)OCTYL]PROPANAMIDE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; CHOLINESTERASE; FLURBIPROFEN; TACRINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYBRID; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT;

ALZHEIMER'S DISEASE; AMYLOID-Β; CHOLINESTERASE INHIBITOR; FLURBIPROFEN; TACRINE;

ACETYLCHOLINESTERASE; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BUTYRYLCHOLINESTERASE; CATALYTIC DOMAIN; CELLS, CULTURED; CHOLINESTERASE INHIBITORS; FEMALE; FLURBIPROFEN; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; TACRINE;

EID: 84889650250     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201300074     Document Type: Article

References (15)

1. H. W. Querfurth, F. M. LaFerla, N. Engl, J. Med. 2010, 362, 329-344.
2. E. Scarpini, P. Scheltens, H. Feldman, Lancet Neurol. 2003, 2, 539-547.
3. U. Holzgrabe, P. Kapková, V. Alptüzün, J. Scheiber, E. Kugelmann, Expert Opin. Ther. Targets 2007, 11, 161-179.
4. C. G. Ballard, Eur. Neurol. 2002, 47, 64-70.
5. J. Hardy, D. J. Selkoe, Science 2002, 297, 353-356.
6. R. Vassar, D. M. Kovacs, R. Yan, P. C. Wong, J. Neurosci. 2009, 29, 12787-12794.
7. I. Peretto, S. Radaelli, C. Parini, M. Zandi, L. F. Raveglia, G. Dondio, L. Fontanella, P. Misiano, C. Bigogno, A. Rizzi, B. Riccardi, M. Biscaioli, S. Marchetti, P. Puccini, S. Catinella, I. Rondelli, V. Cenacchi, P. T. Bolzoni, P. Caruso, G. Villetti, F. Facchinetti, E. D. Giudice, N. Moretto, B. P. Imbimbo, J. Med. Chem. 2005, 48, 5705-5720.
8. M. B. Youdim, J. J. Buccafusso, Trends Pharmacol. Sci. 2005, 26, 27-35.
9. L. Fang, B. Kraus, J. Lehmann, J. Heilmann, Y. H. Zhang, M. Decker, Bioorg. Med. Chem. Lett. 2008, 18, 2905-2909.
10. M. I. Fernández-Bachiller, C. Pérez, G. C. González-Muñoz, S. Conde, M. G. Lõpez, M. Villarroya, A. G. García, M. S. Rodríguez-Franco, J. Med. Chem. 2010, 53, 4927-4937.
11. P. R. Carlier, Y. F. Han, E. S.-H. Chow, C. P.-L. Li, H. Wang, T. X. Lieu, H. S. Wong, Y.-P. Pang, Bioorg. Med. Chem. 1999, 7, 351-357.
12. G. L. Ellman, K. D. Courtney, V. Andres, Jr., R. M. Feather-Stone, Biochem. Pharmacol. 1961, 7, 88-95.
13. Y. Bourne, P. Taylor, Z. Radic̈, P. Marchot, EMBO J. 2003, 22, 1-12.
14. M. Bartolini, C. Bertucci, V. Cavrini, V. Andrisano, Biochem. Pharmacol. 2003, 65, 407-416.
15. T. H. Al-Tel, M. H. Semreen, R. A. Al-Qawasmeh, M. F. Schmidt, R. El-Awadi, M. Ardah, R. Zaarour, S. N. Rao, O. El-Agnaf, J. Med. Chem. 2011, 54, 8373-8385.